Stress chaperones, mortalin, and Pex19p mediate 5-Aza-2′ deoxycytidine-induced senescence of cancer cells by DNA methylation-independent pathway

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 62, Issue 3, 2007, Pages 246-255

  Widodo, Nashi ^a,b   Deocaris, Custer C ^a,c   Kaur, Kamaljit ^a   Hasan, Kamrul ^a   Yaguchi, Tomoko ^a   Yamasaki, Kazuhiko ^a   Sugihara, Takashi ^d   Ishii, Tetsuro ^b   Wadhwa, Renu ^a,c   Kaul, Sunil C ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d INSTITUTE FOR ENVIRONMENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHAPERONE; MORTALIN; PROTEIN P16INK4A; PROTEIN P53; PROTEIN PEX19P; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BIOLOGICAL MARKER; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; LIPOPROTEIN; MEMBRANE PROTEIN; PEX19 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL; CELL AGING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; CHROMATIN; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL MARKERS; CELL AGING; CELL LINE, TUMOR; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIPOPROTEINS; MEMBRANE PROTEINS; MOLECULAR CHAPERONES; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34248568103     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/62.3.246     Document Type: Article

References (76)

1. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005;33:53-61.
2. Enokida H, Shiina H, Igawa M, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004;64:5956-5962.
3. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer. 2003;104:735-744.
4. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
5. Lichtenstein AV, Kisseljova NP. DNA methylation and carcinogenesis. Biochemistry (Mosc). 2001;66:235-255.
6. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59: 3730-3740.
7. Oshimo Y, Nakayama H, Ito R, et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol. 2003;23:1663-1670.
8. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178-1184.
9. Sugimoto S, Maass N, Takimoto Y, et al. Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett. 2004;203:209-215.
10. van der Velden PA, Metzelaar-Blok JA, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001;61:5303-5306.
11. Virmani A, Rathi A, Heda S, et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer. 2003;107:341-345.
12. Yu MY, Tong JH, Chan PK, et al. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer. 2003;105:204-209.
13. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001;61:3581-3585.
14. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632-4642.
15. Hiltunen MO, Turunen MP, Hakkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7:5-11.
16. Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61:4238-4243.
17. Casillas MA Jr, Lopatina N, Andrews LG, Tollefsbol TO. Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts. Mol Cell Biochem. 2003;252:33-43.
18. Vertino PM, Issa JP, Pereira-Smith OM, Baylin SB. Stabilization of DNA methyltransferase levels and CpG island hypermethylation precede SV40-induced immortalization of human fibroblasts. Cell Growth Differ. 1994;5:1395-1402.
19. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59:2302-2306.
20. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 2003;9:4415-4422.
21. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 2002;62:6645-6650.
22. Melki JR, Warnecke P, Vincent PC, Clark SJ. Increased DNA methyltransferase expression in leukaemia. Leukemia. 1998;12:311-316.
23. Nakagawa T, Kanai Y, Saito Y, Kitamura T, Kakizoe T, Hirohashi S. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. J Urol. 2003;170:2463-2466.
24. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology. 2001;33:561-568.
25. Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002;62:4992-4995.
26. Fairweather DS, Fox M, Margison GP. The in vitro lifespan of MRC-5 cells is shortened by 5-azacytidine-induced demethylation. Exp Cell Res. 1987;168:153-159.
27. Holliday R. The inheritance of epigenetic defects. Science. 1987;238:163-170.
28. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene. 2003;22:4118-1127.
29. Suh SI, Pyun HY, Cho JW, et al. 5-Aza-2′-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett. 2000;160:81-88.
30. Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ. 1998;9:139-146.
31. Swafford DS, Middleton SK, Palmisano WA, et al. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol. 1997;17:1366-1374.
32. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 1996;16:859-867.
33. Huschtscha LI, Noble IR, Neumann AA, et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 1998;58:3508-3512.
34. Palmero I, McConnell B, Parry D, et al. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene. 1997;15:495-503.
35. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593-602.
36. Uhrbom L, Nister M, Westermark B. Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene. 1997;15:505-514.
37. Duan J, Zhang Z, Tong T. Senescence delay of human diploid fibroblast induced by anti-sense p16INK4a expression. J Biol Chem. 2001;276:48325-48331.
38. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 1996;56:2886-2890.
39. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol. 2003;51:231-239.
40. Balch C, Montgomery JS, Paik HI, Kim S, Huang TH, Nephew KP. New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci. 2005;10:1897-1931.
41. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 1992;10:205-209.
42. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452.
43. Pohlmann P, DiLeone LP, Cancella Al, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2002;25:496-501.
44. Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-aza-2′ deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 1998;84:87-89.
45. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994;91:11797-11801.
46. Lee S, Tsai FT. Molecular chaperones in protein quality control. J Biochem Mol Biol. 2005;38:259-265.
47. Proctor CJ, Soti C, Boys RJ, et al. Modelling the actions of chaperones and their role in ageing. Mech Ageing Dev. 2005;126:119-131.
48. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280:33097-33100.
49. Wadhwa R, Sugihara T, Hasan MK, Taira K, Reddel RR, Kaul SC. A major functional difference between the mouse and human ARF tumor suppressor proteins. J Biol Chem. 2002;277:36665-36670.
50. Wadhwa R, Ando H, Kawasaki H, Taira K, Kaul SC. Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes. EMBO Rep. 2003;4:595-601.
51. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363-9367.
52. Campisi J. The biology of replicative senescence. Eur J Cancer. 1997;33:703-709.
53. Duncan EL, Wadhwa R, Kaul SC. Senescence and immortalization of human cells. Biogerontology. 2000;1:103-121.
54. Hayflick L. The cell biology of aging. Clin Geriatr Med. 1985;1:15-27.
55. Mazin AL. Life span prediction from the rate of age-related DNA demethylation in normal and cancer cell lines. Exp Gerontol. 1995;30:475-484.
56. Timmermann S, Hinds PW, Munger K. Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene. 1998;17:3445-3453.
57. Veitonmaki N, Fuxe J, Hultdin M, Roos G, Pettersson RF, Cao Y. Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb. FASEB J. 2003; 17:764-766,
58. Wadhwa R, Takano S, Taira K, Kaul SC. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med. 2004;6:439-444.
59. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is overexpressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol. 2005;205:74-81.
60. Srokowski T, Pfeifer JD, Li J, Olson LM, Rader JS. Expression and localization of GRP75 in human epithelial tumors and normal tissues. Appl Immunohistochem Mol Morphol. 2004;12:132-138.
61. Wadhwa R, Takano S, Kaur K, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer. 2006;118:2973-2980.
62. Weller EM, Poot M, Hoehn H. Induction of replicative senescence by 5-azacytidine: fundamental cell kinetic differences between human diploid fibroblasts and NIH-3T3 cells. Cell Prolif. 1993;26:45-54.
63. Wadhwa R, Kaul SC, Mitsui Y, Sugimoto Y. Differential subcellular distribution of mortalin in mortal and immortal mouse and human fibroblasts. Exp Cell Res. 1993;207:442-448.
64. Wadhwa R, Pereira-Smith OM, Reddel RR, Sugimoto Y, Mitsui Y, Kaul SC. Correlation between complementation group for immortality and the cellular distribution of mortalin. Exp Cell Res. 1995;216:101-106.
65. Bertram MJ, Bérubé NG, Hang-Swanson X, et al. Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol. 1999;19:1479-1485.
66. Nakabayashi K, Ogino H, Michishita E, Satoh N, Ayusawa D. Introduction of chromosome 7 suppresses telomerase with shortening of telomeres in a human mesothelial cell line. Exp Cell Res. 1999;252:376-382.
67. Michishita E, Nakabayashi K, Suzuki T, et al. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J Biochem. 1999;126:1052-1059.
68. Wadhwa R, Sugihara T, Yoshida A, et al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000;60:6818-6821.
69. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577-590.
70. Wadhwa R, Takano S, Robert M, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem. 1998;273:29586-29591.
71. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR, Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994;211:90-98.
72. Shibata H, Kashiwayama Y, Imanaka T, Kato H. Domain architecture and activity of human Pex19p, a chaperone-like protein for intracellular trafficking of peroxisomal membrane proteins. J Biol Chem. 2004; 279:38486-38494.
73. Wadhwa R, Taira K, Kaul SC. Mortalin: a potential candidate for biotechnology and biomedicine. Histol Histopathol. 2002;17:1173-1177.
74. Callahan BG. Can hormesis be a default for dose-response? Hum Exp Toxicol. 2005;24:271-273.
75. Rattan SI, Clark BF. Understanding and modulating ageing. IUBMB Life. 2005;57:297-304.
76. Laird PW, laenisch R. DNA methylation and cancer. Hum Mol Genet. 1994;3:1487-1495.